November 21, 2016 - By Winifred Garcia · 0 Comments
The stock of Versartis Incorporated (NASDAQ:VSAR) registered a decrease of 26.59% in short interest. VSAR’s total short interest was 974,200 shares in November as published by FINRA. Its down 26.59% from 1.33M shares, reported previously. With 102,300 shares average volume, it will take short sellers 10 days to cover their VSAR’s short positions. The short interest to Versartis Incorporated’s float is 7.93%. The stock increased 0.38% or $0.05 on November 18, hitting $13.05. Versartis Inc (NASDAQ:VSAR) has risen 32.89% since April 19, 2016 and is uptrending. It has outperformed by 29.03% the S&P500.
Versartis, Inc. is an endocrine-focused biopharmaceutical company. The company has a market cap of $464.77 million. The Firm is engaged in developing long-acting recombinant human growth hormone , somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. It currently has negative earnings. The Company’s product pipeline includes VRS-317 and XTEN Technology.
Insitutional Activity: The institutional sentiment decreased to 2.1 in 2016 Q2. Its down 0.90, from 3 in 2016Q1. The ratio dived, as 5 funds sold all Versartis Inc shares owned while 8 reduced positions. 5 funds bought stakes while 34 increased positions. They now own 20.36 million shares or 0.09% more from 20.34 million shares in 2016Q1.
Aisling Cap Limited owns 2.28M shares or 5.95% of their US portfolio. Jpmorgan Chase & Com holds 856,524 shares or 0% of its portfolio. Tower Research Ltd Com (Trc) has 659 shares for 0% of their US portfolio. Swiss State Bank has invested 0% of its portfolio in Versartis Inc (NASDAQ:VSAR). Schwab Charles Inv Mgmt reported 69,323 shares or 0% of all its holdings. Perceptive Limited Liability holds 2.17% of its portfolio in Versartis Inc (NASDAQ:VSAR) for 2.84 million shares. The New York-based Tiaa Cref Invest Management Llc has invested 0% in Versartis Inc (NASDAQ:VSAR). Credit Suisse Ag has invested 0% of its portfolio in Versartis Inc (NASDAQ:VSAR). Royal Retail Bank Of Canada, a Ontario – Canada-based fund reported 1,200 shares. Blackrock Fund last reported 1.08M shares in the company. Legal & General Grp Inc Public Lc last reported 4,502 shares in the company. Parametric Assoc Llc has 47,728 shares for 0% of their US portfolio. Alliancebernstein L P accumulated 12,800 shares or 0% of the stock. State Street holds 0% or 355,893 shares in its portfolio. Blackrock Invest last reported 113,158 shares in the company.
Insider Transactions: Since June 15, 2016, the stock had 1 insider buy, and 4 insider sales for $6.89 million net activity. Westberg Paul sold $7,707 worth of Versartis Inc (NASDAQ:VSAR) on Wednesday, June 15. $15,392 worth of Versartis Inc (NASDAQ:VSAR) shares were sold by Brumm Joshua T. Varian John sold $20,755 worth of stock or 1,600 shares. $7.00 million worth of Versartis Inc (NASDAQ:VSAR) shares were bought by AKKARAJU SRINIVAS. $70,093 worth of Versartis Inc (NASDAQ:VSAR) was sold by Shepard Jay.
Out of 6 analysts covering Versartis Inc (NASDAQ:VSAR), 4 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 67% are positive. Versartis Inc has been the topic of 8 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The firm earned “Overweight” rating on Tuesday, October 4 by Piper Jaffray. The stock of Versartis Inc (NASDAQ:VSAR) earned “Underperform” rating by Credit Suisse on Thursday, December 17. Credit Suisse initiated the shares of VSAR in a report on Thursday, August 20 with “Neutral” rating. The firm has “Equal Weight” rating by Morgan Stanley given on Thursday, August 13. As per Thursday, April 7, the company rating was initiated by Northland Capital. Canaccord Genuity maintained the stock with “Buy” rating in Monday, September 21 report. The stock of Versartis Inc (NASDAQ:VSAR) has “Buy” rating given on Thursday, August 11 by Citigroup.
Versartis, Inc., incorporated on December 10, 2008, is an endocrine-focused biopharmaceutical company. The Firm is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.
More news for Versartis Inc (NASDAQ:VSAR) were recently published by: Marketwatch.com, which released: “/quotes/zigman/3870025/realtime” on March 21, 2014. Quotes.Wsj.com‘s article titled: “Versartis Inc. VSAR (US: Nasdaq)” and published on March 21, 2014 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Winifred Garcia